Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
61
GOSS Quote, Financials, Valuation and Earnings
Last price:
$2.88
Seasonality move
:
-9.89%
Day range:
$3.08 - $3.21
52-week range:
$0.76 - $3.87
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.85x
P/B ratio:
8.01x
Volume:
3.9M
Avg. volume:
3.9M
1-year change:
196.91%
Market cap:
$666.6M
Revenue:
$114.7M
EPS (TTM):
-$0.69
Analysts' Opinion
-
Consensus RatingGossamer Bio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.50, Gossamer Bio, Inc. has an estimated upside of 229.86% from its current price of $3.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $3.10.
Fair Value
-
According to the consensus of 7 analysts, Gossamer Bio, Inc. has 229.86% upside to fair value with a price target of $9.50 per share.
GOSS vs. S&P 500
-
Over the past 5 trading days, Gossamer Bio, Inc. has underperformed the S&P 500 by -15.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Gossamer Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Gossamer Bio, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Gossamer Bio, Inc. reported revenues of $13.3M.
Earnings Growth
-
Gossamer Bio, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Gossamer Bio, Inc. reported earnings per share of -$0.21.
Enterprise value:
689.2M
EV / Invested capital:
--
Price / LTM sales:
14.85x
EV / EBIT:
--
EV / Revenue:
15.65x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-4.35x
Price / Operating cash flow:
54.59x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$42.2M
Return On Assets:
-55.91%
Net Income Margin (TTM):
-354.5%
Return On Equity:
-615%
Return On Invested Capital:
-81%
Operating Margin:
-313.21%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $105.3M | $44.1M | $9.5M | $13.3M | |
| Gross Profit | -$4.5M | $101.3M | $42.2M | $8.4M | $13.1M | |
| Operating Income | -$189M | -$62.8M | -$153.3M | -$33.9M | -$41.6M | |
| EBITDA | -$184.5M | -$58.8M | -$151.5M | -$32.8M | -$41.4M | |
| Diluted EPS | -$1.76 | -$0.33 | -$0.69 | -$0.14 | -$0.21 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $374M | $312M | $341.5M | $344.3M | $204M | |
| Total Assets | $387M | $323.5M | $347.9M | $350.9M | $208.8M | |
| Current Liabilities | $35.9M | $52.6M | $42.3M | $51.1M | $62.1M | |
| Total Liabilities | $217.2M | $267.2M | $243.3M | $296.7M | $291.2M | |
| Total Equity | $169.8M | $56.4M | $104.6M | $54.1M | -$82.3M | |
| Total Debt | $184.4M | $226.2M | $212.6M | $201.9M | $202M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$173.5M | -$1.4M | -$158.4M | -$32M | -$36.2M | |
| Cash From Investing | -$88.1M | -$38.6M | $136.4M | -$26.8M | $17M | |
| Cash From Financing | $190.2M | -$14.4M | $2.5M | $281K | $1.9M | |
| Free Cash Flow | -$173.6M | -$1.4M | -$158.5M | -$32M | -$36.2M | |
GOSS
Sector
Market Cap
$666.6M
$28.2M
Price % of 52-Week High
74.42%
50.98%
Dividend Yield
0%
0%
Shareholder Yield
-0.54%
-1.55%
1-Year Price Total Return
196.91%
-17.58%
Beta (5-Year)
1.922
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.32
200-day SMA
Buy
Level
$2.02
Bollinger Bands (100)
Buy
Level
2.27 - 3.27
Chaikin Money Flow
Sell
Level
-15.6M
20-day SMA
Sell
Level
$3.43
Relative Strength Index (RSI14)
Sell
Level
45.03
ADX Line
Sell
Level
22.18
Williams %R
Buy
Level
-97.0588
50-day SMA
Buy
Level
$2.98
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
22.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.4577)
Sell
CA Score
(Annual)
Level (-2.8036)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.2862)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, GOSS has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The GOSS average analyst price target in the past 3 months is $9.50.
-
Where Will Gossamer Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Gossamer Bio, Inc. share price will rise to $9.50 per share over the next 12 months.
-
What Do Analysts Say About Gossamer Bio, Inc.?
Analysts are divided on their view about Gossamer Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Gossamer Bio, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Gossamer Bio, Inc.'s Price Target?
The price target for Gossamer Bio, Inc. over the next 1-year time period is forecast to be $9.50 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is GOSS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Gossamer Bio, Inc. is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GOSS?
You can purchase shares of Gossamer Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Gossamer Bio, Inc. shares.
-
What Is The Gossamer Bio, Inc. Share Price Today?
Gossamer Bio, Inc. was last trading at $2.88 per share. This represents the most recent stock quote for Gossamer Bio, Inc.. Yesterday, Gossamer Bio, Inc. closed at $3.10 per share.
-
How To Buy Gossamer Bio, Inc. Stock Online?
In order to purchase Gossamer Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get GOSS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GOSS
Sector
P/E ratio
--
24.09x
PEG ratio
-0.04x
-0.01x
P/B ratio
8.01x
1.81x
Price / LTM sales
14.85x
1.59x
Growth Metrics
GOSS
Sector
Revenue growth
40.23%
4.68%
Earnings growth
-55.4%
11.06%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.21
-$0.18
Profitability
GOSS
Sector
Profitability FY 2024
$110.6M
$3.6M
Return on invested capital
-81%
-31.84%
Return on assets
-55.91%
-28.18%
Return on equity
-615%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
4
Balance Sheet
GOSS
Sector
Total cash
$180.2M
$26.3M
Short term investments
$248.4M
$26M
Total assets
$315.3M
$76.7M
Long term debt
$202M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 4
Claritev Corp. [CTEV] is down 20.7% over the past day.
Buy
60
BIDU alert for Jan 3
Baidu, Inc. [BIDU] is up 15.01% over the past day.
Sell
47
ASTS alert for Jan 4
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
